Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?

[1]  Nanhua Zhang,et al.  The Stability and Influence of Barriers to Medication Adherence on Seizure Outcomes and Adherence in Children With Epilepsy Over 2 Years , 2018, Journal of pediatric psychology.

[2]  A. Modi,et al.  Assessing barriers to adherence in routine clinical care for pediatric kidney transplant patients , 2017, Pediatric transplantation.

[3]  Pooja Mehta,et al.  Medication adherence among adolescent solid‐organ transplant recipients: A survey of healthcare providers , 2017, Pediatric transplantation.

[4]  A. Hagihara,et al.  Physicians’ and pharmacists’ information provision and patients’ psychological distress , 2017, Journal of interprofessional care.

[5]  C. Gross,et al.  Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. , 2017, JCO clinical cancer informatics.

[6]  Shoshana M. Rosenberg,et al.  Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer , 2017, Current Breast Cancer Reports.

[7]  Lyndsay D. Hughes,et al.  Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review , 2017, Patient preference and adherence.

[8]  J. Lewin,et al.  Elevating pharmacists' scope of practice through a health-system clinical privileging process. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  V. Sheppard,et al.  Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review. , 2016, Clinical breast cancer.

[10]  Aaron N. Winn,et al.  The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer , 2016, Pharmacoepidemiology and drug safety.

[11]  V. Sheppard,et al.  Rethinking agency and medical adherence technology: applying Actor Network Theory to the case study of Digital Pills. , 2015, Nursing inquiry.

[12]  T. A. Mason,et al.  Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. , 2014, Patient education and counseling.

[13]  E. Bergeron,et al.  Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. , 2014, Canadian journal of surgery. Journal canadien de chirurgie.

[14]  A. Baldoni,et al.  Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer , 2014, International Journal of Clinical Pharmacy.

[15]  Andreas Bock,et al.  Medication Adherence Assessment: High Accuracy of the New Ingestible Sensor System in Kidney Transplants , 2013, Transplantation.

[16]  D. Petrie,et al.  The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study , 2013, British Journal of Cancer.

[17]  Roy H Perlis,et al.  First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. , 2013, The Journal of clinical psychiatry.

[18]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[19]  L. Huiart,et al.  A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians , 2013, Breast Cancer Research and Treatment.

[20]  R. Reves,et al.  Feasibility of an Ingestible Sensor-Based System for Monitoring Adherence to Tuberculosis Therapy , 2013, PloS one.

[21]  A. Thind,et al.  Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication , 2013, Breast Cancer Research and Treatment.

[22]  A. Neugut,et al.  Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Kravitz,et al.  Provider Views About Responsibility for Medication Adherence and Content of Physician–Older Patient Discussions , 2012, Journal of the American Geriatrics Society.

[24]  L. Huiart,et al.  Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Dennis Ross-Degnan,et al.  Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer , 2011, Breast Cancer Research and Treatment.

[26]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[27]  C. Dawson-Rose,et al.  A Qualitative Study of Providers' Perception of Adherence of Women Living with HIV/AIDS in Puerto Rico. , 2010, Qualitative report.

[28]  M. Dimatteo,et al.  Physician Communication and Patient Adherence to Treatment : A Meta-analysis , 2018 .

[29]  C. Hudis,et al.  Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. , 2008, Clinical breast cancer.

[30]  Eric C. Schneider,et al.  Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use , 2007, Medical care.

[31]  V. Vogel,et al.  Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. , 2007, The journal of supportive oncology.

[32]  L. Fallowfield,et al.  Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy , 2007, Breast Cancer Research and Treatment.

[33]  Timothy L. Lash,et al.  Adherence to tamoxifen over the five-year course , 2006, Breast Cancer Research and Treatment.

[34]  Louise Atkins,et al.  Intentional and non-intentional non-adherence to medication amongst breast cancer patients. , 2005, European journal of cancer.

[35]  E. Grunfeld,et al.  Adherence beliefs among breast cancer patients taking tamoxifen. , 2005, Patient education and counseling.

[36]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[37]  Nicholas Ladany,et al.  Consensual Qualitative Research: An Update , 2005 .

[38]  P. Butow,et al.  Discussing adjuvant cancer therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Farmer,et al.  Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. , 1999, Clinical therapeutics.

[40]  M. E. Harrison,et al.  Impact of side-effects associated with endocrine treatments for advanced breast cancer: clinicians' and patients' perceptions , 1996 .

[41]  J. de Haes,et al.  Doctor-patient communication: a review of the literature. , 1995, Social science & medicine.